These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26380223)

  • 1. Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation.
    Geier B; Kurmashev D; Kurmasheva RT; Houghton PJ
    Front Oncol; 2015; 5():193. PubMed ID: 26380223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
    Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying novel therapeutic agents using xenograft models of pediatric cancer.
    Kurmasheva RT; Houghton PJ
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):221-32. PubMed ID: 27193096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
    Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
    Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
    Hingorani P; Zhang W; Piperdi S; Pressman L; Lin J; Gorlick R; Kolb EA
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of adjuvant chemotherapy in the management of sarcomas in children.
    Donaldson SS
    Cancer; 1985 May; 55(9 Suppl):2184-97. PubMed ID: 3884137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
    Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
    Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
    Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
    Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
    Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
    J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
    Pascual-Pasto G; Resa-Pares C; Castillo-Ecija H; Aschero R; Baulenas-Farres M; Vila-Ubach M; Burgueño V; Balaguer-Lluna L; Cuadrado-Vilanova M; Olaciregui NG; Martinez-Velasco N; Perez-Jaume S; de Alava E; Tirado OM; Lavarino C; Mora J; Carcaboso AM
    Biochem Pharmacol; 2023 Feb; 208():115408. PubMed ID: 36603685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
    Bandyopadhyay A; Favours E; Phelps DA; Pozo VD; Ghilu S; Kurmashev D; Michalek J; Trevino A; Guttridge D; London C; Hirotani K; Zhang L; Kurmasheva RT; Houghton PJ
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29080385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of the pediatric preclinical testing panel.
    Neale G; Su X; Morton CL; Phelps D; Gorlick R; Lock RB; Reynolds CP; Maris JM; Friedman HS; Dome J; Khoury J; Triche TJ; Seeger RC; Gilbertson R; Khan J; Smith MA; Houghton PJ
    Clin Cancer Res; 2008 Jul; 14(14):4572-83. PubMed ID: 18628472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
    Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
    Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
    Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical experimental therapeutic approaches in soft tissue sarcoma.
    Hunt KK; Feig BW
    Semin Surg Oncol; 1999; 17(1):78-82. PubMed ID: 10402641
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Cornillie J; Wozniak A; Pokreisz P; Casazza A; Vreys L; Wellens J; Vanleeuw U; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    Mol Cancer Ther; 2017 Aug; 16(8):1566-1575. PubMed ID: 28566438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas.
    Dancsok AR; Setsu N; Gao D; Blay JY; Thomas D; Maki RG; Nielsen TO; Demicco EG
    Mod Pathol; 2019 Dec; 32(12):1772-1785. PubMed ID: 31263176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.